LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL). LX2931 works by increasing levels of S1P inside and outside the cell. The decrease in S1PL activity leads to a significant increase in S1P content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the treatment of autoimmune diseases, especially rheumatoid arthritis.
References:
[1]. Bagdanoff J T, et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1 R, 2 S, 3 R)-1, 2, 3, 4-tetradroxybutyl)-1 H-imidazol-2-yl) ethanone oxime (LX2931) and (1 R, 2 S, 3 R)-1-(2-(isoxazol-3-yl)-1 H-imidazol-4-yl) butane-1, 2, 3, 4-tetraol (LX2932)[J]. Journal of medicinal chemistry, 2010, 53(24): 8650-8662.